{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:47:47Z","timestamp":1776930467451,"version":"3.51.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11916-026-01486-4","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:13:35Z","timestamp":1776928415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Efficacy and Safety of Rimegepant Every Other Day as Preventive Treatment for Migraine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"30","author":[{"given":"Ahmed","family":"Attar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4020-0986","authenticated-orcid":false,"given":"Abdalmajed","family":"Alqsair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4513-2819","authenticated-orcid":false,"given":"Mumen","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Barwais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldanah","family":"Alzaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renad","family":"Alshaikhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujain","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasen","family":"Aljadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joury","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmeen","family":"Zagzoog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Aladdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"1486_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:954\u201376.","journal-title":"Lancet Neurol"},{"key":"1486_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world\u2019s causes of disability, and first among young women. J Headache Pain. 2020;21:137.","journal-title":"J Headache Pain"},{"key":"1486_CR3","first-page":"343","volume":"81","author":"DC Buse","year":"2013","unstructured":"Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and socioeconomic burden. Neurology. 2013;81:343\u201352.","journal-title":"Neurology"},{"key":"1486_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ncl.2008.11.007","volume":"27","author":"SD Silberstein","year":"2009","unstructured":"Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009;27:429\u201343.","journal-title":"Neurol Clin"},{"key":"1486_CR5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(17)30415-5","volume":"17","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Lancet Neurol. 2018;17:391\u20132.","journal-title":"Lancet Neurol"},{"key":"1486_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553\u2013622.","journal-title":"Physiol Rev"},{"key":"1486_CR7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant for the acute treatment of migraine. N Engl J Med. 2019;381:142\u20139.","journal-title":"N Engl J Med"},{"key":"1486_CR8","first-page":"1120","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW. Gepants for the treatment and prevention of migraine. Headache. 2020;60:1120\u20136.","journal-title":"Headache"},{"key":"1486_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-017-0813-3","volume":"18","author":"DD Mitsikostas","year":"2017","unstructured":"Mitsikostas DD, Belesioti I, Arvaniti C, et al. Patients\u2019 preferences for headache acute and preventive treatment. J Headache Pain. 2017;18:102.","journal-title":"J Headache Pain"},{"issue":"10268","key":"1486_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomized, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51\u201360.","journal-title":"Lancet"},{"issue":"8","key":"1486_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/head.14995","volume":"65","author":"S Kitamura","year":"2025","unstructured":"Kitamura S, Matsumori Y, Yamamoto T, Ishikawa T, Hoshino Y, Yoshimatsu H, et al. Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: a double-blind, randomized controlled trial. Headache. 2025;65(8):1403\u201312. https:\/\/doi.org\/10.1111\/head.14995.","journal-title":"Headache"},{"issue":"11","key":"1486_CR12","doi-asserted-by":"publisher","first-page":"033310242513913","DOI":"10.1177\/03331024251391378","volume":"45","author":"P Pozo-Rosich","year":"2025","unstructured":"Pozo-Rosich P, L\u00f3pez JAG, Lisewski P, Aslan AN, Seehra H, Thiry A, et al. A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications. Cephalalgia. 2025;45(11):03331024251391378.","journal-title":"Cephalalgia"},{"issue":"4","key":"1486_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garc\u00eda-Azor\u00edn D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43(4):033310242311593. https:\/\/doi.org\/10.1177\/03331024231159366.","journal-title":"Cephalalgia"},{"issue":"18 Suppl","key":"1486_CR14","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1212\/WNL.98.18_supplement.2972","volume":"98","author":"E Popoff","year":"2022","unstructured":"Popoff E, Powell L, Johnston K, O\u2019Sullivan F, Harris L, Leroue C, et al. Rimegepant versus atogepant and monoclonal antibody treatments for the prevention of migraine: a systematic literature review and network meta-analysis. Neurology. 2022;98(18 Suppl):2972.","journal-title":"Neurology"},{"key":"1486_CR15","doi-asserted-by":"crossref","unstructured":"Medrea I, Cooper P, Langman M, Sandoe CH, Amoozegar F, Hussain WM et al. Updated Canadian Headache Society migraine prevention guideline with systematic review and meta-analysis. Can J Neurol Sci. 2024;1\u201323. Available from: PubMed.","DOI":"10.1017\/cjn.2024.285"},{"issue":"3","key":"1486_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia. 2023;43(3):033310242311521.","journal-title":"Cephalalgia"},{"key":"1486_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1611303","author":"MK V\u00e9lez-Jim\u00e9nez","year":"2025","unstructured":"V\u00e9lez-Jim\u00e9nez MK, Mart\u00ednez-Mayorga AP, Rodriguez-Leyva I, Figueroa-Medina MJ, Reyes-Alvarez MT, P\u00e9rez-Garc\u00eda JC, et al. Comprehensive preventive treatments for episodic migraine: a systematic review of randomized clinical trials. Front Neurol. 2025;16:1611303. https:\/\/doi.org\/10.3389\/fneur.2025.1611303","journal-title":"Front Neurol"},{"key":"1486_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241235156","author":"C Tassorelli","year":"2024","unstructured":"Tassorelli C, Onishchenko K, Halker Singh RB, Duan M, Dupont-Benjamin L, Hemstock M, et al. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. Cephalalgia. 2024;44(2):3331024241235156. https:\/\/doi.org\/10.1177\/03331024241235156","journal-title":"Cephalalgia"},{"key":"1486_CR19","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-00315","author":"JAA Damen","year":"2025","unstructured":"Damen JAA, Yang B, Idema DL, Vernooij RWM, Huis In \u2019t Veld L, Kusters M, et al. Comparative effectiveness of pharmacologic treatments for the prevention of episodic migraine headache: A systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med. 2025;178(3):369\u2013380. https:\/\/doi.org\/10.7326\/ANNALS-24-00315","journal-title":"Ann Intern Med"},{"key":"1486_CR20","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Available from: https:\/\/prisma-statement.org\/","DOI":"10.1136\/bmj.n71"},{"issue":"1","key":"1486_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2020","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2020;12(1):55\u201361.","journal-title":"Res Synth Methods"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-026-01486-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:13:39Z","timestamp":1776928419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-026-01486-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1007\/s11916-026-01486-4","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}